.:. Consulter > Par domaine > Sciences du Vivant/Biochimie, Biologie Moléculaire .:.

1874 documents classés par :  date titre 1er auteur

1 - 2 - 3 - 4 - 5 - 6 - 7 ...

Kinetic approaches to lactose operon induction and bimodality. Michel D. Journal of Theoretical Biology 325 (2013) 62-75 [inserm-00818506 - version 1]

Death receptors as targets in cancer Micheau O., Shirley S., Dufour F. [inserm-00823459 - version 1] (17/05/2013)

AhR- and NF-κB-dependent induction of interleukin-6 by co-exposure to the environmental contaminant benzanthracene and the cytokine tumor necrosis factor-α in human mammary MCF-7 cells. Kolasa E., Houlbert N., Balaguer P., Fardel O. Chemico-Biological Interactions 203, 2 (2013) 391-400 [inserm-00818896 - version 1]

Anti-hyperglycemic effects of three medicinal plants in diabetic pregnancy: modulation of T cell proliferation. Yessoufou A., Gbenou J., Grissa O., Hichami A., Simonin A.-M., Tabka Z., Moudachirou M., Moutairou K., Khan N. BMC Complementary and Alternative Medicine 13, 1 (2013) 77 [inserm-00818230 - version 1]

Cholesterol transport via ABCA1: New insights from solid-phase binding assay. Reboul E., Dyka F. M., Quazi F., Molday R. S. Biochimie 95, 4 (2013) 957-61 [inserm-00765921 - version 1]

Reporting of analyses from randomized controlled trials with multiple arms: a systematic review. Baron G., Perrodeau E., Boutron I., Ravaud P. BMC Medicine 11, 1 (2013) 84 [inserm-00809311 - version 1]

THE FARNESOID X RECEPTOR INHIBITS THE TRANSCRIPTIONAL ACTIVITY OF THE CARBOHYDRATE RESPONSE ELEMENT BINDING PROTEIN IN HUMAN HEPATOCYTES -- R2. Caron S., Samanez C. H., Dehondt H., Ploton M., Briand O., Lien F., Dorchies E., Dumont J., Postic C., Cariou B. et al Mol Cell Biol (2013) epub ahead of print [inserm-00806064 - version 1]

Hypersomnia and depressive symptoms: methodological and clinical aspects. Dauvilliers Y., Lopez R., Ohayon M., Bayard S. BMC Medicine 11, 1 (2013) 78 [inserm-00809240 - version 1]

Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx). Bruera G., Cannita K., Di Giacomo D., Lamy A., Frébourg T., Sabourin J. C., Tosi M., Alesse E., Ficorella C., Ricevuto E. BMC Medicine 11, 1 (2013) 59 [inserm-00817083 - version 1]

BiNoM 2.0, a Cytoscape plugin for accessing and analyzing pathways using standard systems biology formats. Bonnet E., Calzone L., Rovera D., Stoll G., Barillot E., Zinovyev A. BMC Systems Biology 7, 1 (2013) 18 [inserm-00820930 - version 1]

1 - 2 - 3 - 4 - 5 - 6 - 7 ...